News
FDA Grants Orphan Drug Designation to Sanofi’s Rare Disease Drug Rilzabrutinib for wAIHA & IgG4-RD
Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...
FDA Grants Orphan Drug Status to Sanofi’s Rilzabrutinib: A New Hope for wAIHA, IgG4-RD, and Beyond
Rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation from the FDA for treating warm autoimmune hemolytic an ...
Your body can produce an infinite number of binding sites to bind to antigens. Immunoglobulin G (IgG) accounts for around 75% of all antibodies in the human body. Depending on the antigen, IgG can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback